Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease

NCT01127633 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01127633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01127633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2010
Completion date
February 28, 2017
Enrollment
1,457 (actual)
Sites
147

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease